Halozyme Therapeutics Stock Fair Value Calculator – HALOZYME THERAPEUTICS Reports 45.1% Year-Over-Year Increase in Total Revenue for Second Quarter of FY2023

☀️Earnings Overview

For the second quarter of FY2023, HALOZYME THERAPEUTICS ($NASDAQ:HALO) reported total revenue of USD 221.0 million, representing a year-over-year increase of 45.1%. This was accompanied by a net income of USD 74.8 million, a significant growth from the same quarter the previous year, which was USD 22.7 million.

Analysis – Halozyme Therapeutics Stock Fair Value Calculator

GoodWhale has conducted an analysis of HALOZYME THERAPEUTICS‘ financials in order to determine the fair value of the company’s shares. According to our proprietary Valuation Line, the fair value of HALOZYME THERAPEUTICS shares is approximately $71.8. This means that the stock is currently being undervalued by 39.7%, as it is currently being traded at $43.3. It is definitely worth considering investing in this undervalued stock, as there may be a reward to be reaped if the true market value of the shares is realized. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Halozyme Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Halozyme Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Halozyme Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Halozyme Therapeutics are shown below. More…

Peers

The Company’s enzyme-based product candidates target the tumor microenvironment, enabling the delivery of cancer drugs directly to the site of the tumor. Halozyme has four product candidates in clinical development, PEGPH20, Hylenex, HALO-102 and HALO-201. Keymed Biosciences Inc, Verona Pharma PLC, Xencor Inc are Halozyme’s competitors in the biopharmaceutical market.

– Keymed Biosciences Inc ($SEHK:02162)

Keymed Biosciences Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer and other serious diseases. The company’s market cap is 12.95B as of 2022 and has a ROE of -4.34%. Keymed Biosciences Inc’s products are designed to target key drivers of disease progression and to provide patients with new treatment options. The company’s lead product, KEY-184, is a first-in-class, orally-available small molecule inhibitor of the MDM2 oncoprotein.

– Verona Pharma PLC ($NASDAQ:VRNA)

Verona Pharma PLC is a pharmaceutical company that focuses on the development of drugs for the treatment of respiratory diseases. The company has a market cap of 790.27M as of 2022 and a Return on Equity of -28.69%. Verona Pharma PLC is headquartered in London, United Kingdom.

– Xencor Inc ($NASDAQ:XNCR)

Xencor Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company’s market cap as of 2022 is 1.64B with a ROE of 4.05%. Xencor is currently working on several clinical-stage programs including XmAb5871 for the treatment of B-cell malignancies, autoimmune diseases, and asthma.

Summary

Halozyme Therapeutics reported total revenue of USD 221.0 million for the second quarter of FY2023, reflecting a 45.1% year-over-year increase. The company’s reported net income for the same period was USD 74.8 million, compared to the previous year’s figure of 22.7 million. This resulted in a stock price rise.

From an investment perspective, Halozyme Therapeutics looks to be an attractive option, given its impressive financial performance and growth prospects. The company’s strong revenue and profitability suggest a healthy outlook, and could provide a potential opportunity for investors to reap rewards in the long-term.